CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
Reminder: On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the ch...
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
Daylight Saving Time Begins March 10, 2019. As a friendly reminder, airlines often change their rout...